FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378902940> ?p ?o ?g. }

• W4378902940 endingPage "101577" @default.
• W4378902940 startingPage "101577" @default.
• W4378902940 abstract "•Patients with impaired renal function have a high risk of being misclassified using a uracil-based DPD phenotyping.•Samples for uracil-based DPD phenotyping during transient renal failure should be collected after renal function recovery.•It seems more relevant for dialyzed patients to collect samples for uracil-based DPD phenotyping after dialysis. BackgroundThe chemotherapeutic agent 5-fluorouracil (5-FU) is catabolized by dihydropyrimidine dehydrogenase (DPD), the deficiency of which may lead to severe toxicity or death. Since 2019, DPD deficiency testing, based on uracilemia, is mandatory in France and recommended in Europe before initiating fluoropyrimidine-based regimens. However, it has been recently shown that renal impairment may impact uracil concentration and thus DPD phenotyping.Patients and methodsThe impact of renal function on uracilemia and DPD phenotype was studied on 3039 samples obtained from three French centers. We also explored the influence of dialysis and measured glomerular filtration rate (mGFR) on both parameters. Finally, using patients as their own controls, we assessed as to what extent modifications in renal function impacted uracilemia and DPD phenotyping.ResultsWe observed that uracilemia and DPD-deficient phenotypes increased concomitantly to the severity of renal impairment based on the estimated GFR, independently and more critically than hepatic function. This observation was confirmed with the mGFR. The risk of being classified ‘DPD deficient’ based on uracilemia was statistically higher in patients with renal impairment or dialyzed if uracilemia was measured before dialysis but not after. Indeed, the rate of DPD deficiency decreased from 86.4% before dialysis to 13.7% after. Moreover, for patients with transient renal impairment, the rate of DPD deficiency dropped dramatically from 83.3% to 16.7% when patients restored their renal function, especially in patients with an uracilemia close to 16 ng/ml.ConclusionsDPD deficiency testing using uracilemia could be misleading in patients with renal impairment. When possible, uracilemia should be reassessed in case of transient renal impairment. For patients under dialysis, testing of DPD deficiency should be carried out on samples taken after dialysis. Hence, 5-FU therapeutic drug monitoring would be particularly helpful to guide dose adjustments in patients with elevated uracil and renal impairment. The chemotherapeutic agent 5-fluorouracil (5-FU) is catabolized by dihydropyrimidine dehydrogenase (DPD), the deficiency of which may lead to severe toxicity or death. Since 2019, DPD deficiency testing, based on uracilemia, is mandatory in France and recommended in Europe before initiating fluoropyrimidine-based regimens. However, it has been recently shown that renal impairment may impact uracil concentration and thus DPD phenotyping. The impact of renal function on uracilemia and DPD phenotype was studied on 3039 samples obtained from three French centers. We also explored the influence of dialysis and measured glomerular filtration rate (mGFR) on both parameters. Finally, using patients as their own controls, we assessed as to what extent modifications in renal function impacted uracilemia and DPD phenotyping. We observed that uracilemia and DPD-deficient phenotypes increased concomitantly to the severity of renal impairment based on the estimated GFR, independently and more critically than hepatic function. This observation was confirmed with the mGFR. The risk of being classified ‘DPD deficient’ based on uracilemia was statistically higher in patients with renal impairment or dialyzed if uracilemia was measured before dialysis but not after. Indeed, the rate of DPD deficiency decreased from 86.4% before dialysis to 13.7% after. Moreover, for patients with transient renal impairment, the rate of DPD deficiency dropped dramatically from 83.3% to 16.7% when patients restored their renal function, especially in patients with an uracilemia close to 16 ng/ml. DPD deficiency testing using uracilemia could be misleading in patients with renal impairment. When possible, uracilemia should be reassessed in case of transient renal impairment. For patients under dialysis, testing of DPD deficiency should be carried out on samples taken after dialysis. Hence, 5-FU therapeutic drug monitoring would be particularly helpful to guide dose adjustments in patients with elevated uracil and renal impairment." @default.
• W4378902940 created "2023-06-01" @default.
• W4378902940 creator A5000924604 @default.
• W4378902940 creator A5004357356 @default.
• W4378902940 creator A5011912541 @default.
• W4378902940 creator A5014695071 @default.
• W4378902940 creator A5020169596 @default.
• W4378902940 creator A5064499434 @default.
• W4378902940 creator A5088425379 @default.
• W4378902940 date "2023-06-01" @default.
• W4378902940 modified "2023-10-01" @default.
• W4378902940 title "Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping" @default.
• W4378902940 cites W1504216369 @default.
• W4378902940 cites W1965311643 @default.
• W4378902940 cites W2082413984 @default.
• W4378902940 cites W2100494110 @default.
• W4378902940 cites W2108822380 @default.
• W4378902940 cites W2113414095 @default.
• W4378902940 cites W2405370499 @default.
• W4378902940 cites W2606453095 @default.
• W4378902940 cites W2613578321 @default.
• W4378902940 cites W2788695304 @default.
• W4378902940 cites W2791644192 @default.
• W4378902940 cites W2791651115 @default.
• W4378902940 cites W3159357568 @default.
• W4378902940 cites W3170399676 @default.
• W4378902940 cites W3199266876 @default.
• W4378902940 cites W4200111980 @default.
• W4378902940 cites W4229073245 @default.
• W4378902940 cites W4290674379 @default.
• W4378902940 cites W4294001357 @default.
• W4378902940 cites W4295903340 @default.
• W4378902940 cites W4303962043 @default.
• W4378902940 cites W4316686767 @default.
• W4378902940 cites W4324311184 @default.
• W4378902940 doi "https://doi.org/10.1016/j.esmoop.2023.101577" @default.
• W4378902940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37267808" @default.
• W4378902940 hasPublicationYear "2023" @default.
• W4378902940 type Work @default.
• W4378902940 citedByCount "0" @default.
• W4378902940 crossrefType "journal-article" @default.
• W4378902940 hasAuthorship W4378902940A5000924604 @default.
• W4378902940 hasAuthorship W4378902940A5004357356 @default.
• W4378902940 hasAuthorship W4378902940A5011912541 @default.
• W4378902940 hasAuthorship W4378902940A5014695071 @default.
• W4378902940 hasAuthorship W4378902940A5020169596 @default.
• W4378902940 hasAuthorship W4378902940A5064499434 @default.
• W4378902940 hasAuthorship W4378902940A5088425379 @default.
• W4378902940 hasBestOaLocation W43789029401 @default.
• W4378902940 hasConcept C123321153 @default.
• W4378902940 hasConcept C126322002 @default.
• W4378902940 hasConcept C126894567 @default.
• W4378902940 hasConcept C143998085 @default.
• W4378902940 hasConcept C159641895 @default.
• W4378902940 hasConcept C181199279 @default.
• W4378902940 hasConcept C185592680 @default.
• W4378902940 hasConcept C2776694085 @default.
• W4378902940 hasConcept C2777318727 @default.
• W4378902940 hasConcept C2778050828 @default.
• W4378902940 hasConcept C2779554091 @default.
• W4378902940 hasConcept C2779978075 @default.
• W4378902940 hasConcept C2780456651 @default.
• W4378902940 hasConcept C29730261 @default.
• W4378902940 hasConcept C552990157 @default.
• W4378902940 hasConcept C55493867 @default.
• W4378902940 hasConcept C71924100 @default.
• W4378902940 hasConcept C90924648 @default.
• W4378902940 hasConceptScore W4378902940C123321153 @default.
• W4378902940 hasConceptScore W4378902940C126322002 @default.
• W4378902940 hasConceptScore W4378902940C126894567 @default.
• W4378902940 hasConceptScore W4378902940C143998085 @default.
• W4378902940 hasConceptScore W4378902940C159641895 @default.
• W4378902940 hasConceptScore W4378902940C181199279 @default.
• W4378902940 hasConceptScore W4378902940C185592680 @default.
• W4378902940 hasConceptScore W4378902940C2776694085 @default.
• W4378902940 hasConceptScore W4378902940C2777318727 @default.
• W4378902940 hasConceptScore W4378902940C2778050828 @default.
• W4378902940 hasConceptScore W4378902940C2779554091 @default.
• W4378902940 hasConceptScore W4378902940C2779978075 @default.
• W4378902940 hasConceptScore W4378902940C2780456651 @default.
• W4378902940 hasConceptScore W4378902940C29730261 @default.
• W4378902940 hasConceptScore W4378902940C552990157 @default.
• W4378902940 hasConceptScore W4378902940C55493867 @default.
• W4378902940 hasConceptScore W4378902940C71924100 @default.
• W4378902940 hasConceptScore W4378902940C90924648 @default.
• W4378902940 hasIssue "3" @default.
• W4378902940 hasLocation W43789029401 @default.
• W4378902940 hasLocation W43789029402 @default.
• W4378902940 hasLocation W43789029403 @default.
• W4378902940 hasOpenAccess W4378902940 @default.
• W4378902940 hasPrimaryLocation W43789029401 @default.
• W4378902940 hasRelatedWork W2015472482 @default.
• W4378902940 hasRelatedWork W2066957784 @default.
• W4378902940 hasRelatedWork W2079683461 @default.
• W4378902940 hasRelatedWork W2163261737 @default.
• W4378902940 hasRelatedWork W2243745165 @default.
• W4378902940 hasRelatedWork W2331160204 @default.
• W4378902940 hasRelatedWork W2509590939 @default.

• next